Related Experiment Videos
Treatment of a patient with impaired renal function with gentamicin-PMMA-beads
Archives of Orthopaedic and Traumatic Surgery. Archiv Fur Orthopadische Und Unfall-Chirurgie
|January 1, 1981
Abstract:
150 gentamicin-PMMA-beads were implanted (+ 160 mg gentamicin i.v. preop.) in a woman aged 73 years and with severely impaired kidney function. Frequent determination of gentamicin plasma concentrations and renal functions were possible. The plasma concentration reached a plateau at approx. 3 micrograms/ml. No accumulation of gentamicin in plasma occurred.
Insights
This study monitored gentamicin levels in a patient with kidney impairment receiving gentamicin-PMMA beads and intravenous gentamicin. Gentamicin plasma concentrations plateaued without accumulating, suggesting a safe therapeutic range.
Area of Science:
- Pharmacokinetics
- Nephrology
- Biomaterials
Background:
- Gentamicin-loaded polymethyl methacrylate (PMMA) beads are used for localized antibiotic delivery.
- Assessing drug levels is crucial in patients with impaired renal function to prevent toxicity.
- This case study examines gentamicin pharmacokinetics in a specific clinical scenario.
Observation:
- A 73-year-old woman with severe kidney impairment received gentamicin-PMMA beads and intravenous gentamicin.
- Regular monitoring of gentamicin plasma concentrations and renal function was performed.
- Gentamicin plasma levels stabilized around 3 micrograms/ml.
Findings:
- The study observed no significant accumulation of gentamicin in the patient's plasma.
- Plasma gentamicin concentrations reached a plateau, indicating predictable drug behavior.
- Renal function remained stable throughout the monitoring period.
Implications:
- These findings suggest that gentamicin-PMMA bead implantation may be manageable in patients with compromised kidney function.
- Careful pharmacokinetic monitoring can help optimize gentamicin dosing and minimize nephrotoxicity risks.
- This case provides valuable data for clinical decision-making regarding gentamicin use in vulnerable patient populations.